

**VERTEX PHARMACEUTICALS INCORPORATED**

130 Waverly Street
Cambridge, MA 02139-4242
Tel. 617.444.6100 Fax 617.444.6680
www.vrtx.com

FAX**RECEIVED
CENTRAL FAX CENTER**

MAY 03 2005

To	Commissioner for Patents
Company	USPTO
FAX	(703) 746-4060
From	Lisa A. Dixon
Date	May 3, 2005
Subject	Application No. 09/877,832 Attorney Docket No. VPI/00-117 US Response to Office Action
Total Pages	10

Message or Comment**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this correspondence, and any documents referred to as attached hereto, is/are being transmitted to the United States Patent and Trademark Office, Facsimile Number: (703) 746-4060 on May 3, 2005.

Lisa Dixon

If any problems occur with this fax transmittal, please call (617) 444-6832 immediately.

FAX Number (617) 444-6483 Legal Department

RECEIVED
MAY - 5 2005
OPIE/JCWS

CONFIDENTIALITY NOTICE

The information and the documents transmitted by this telecopy are privileged and contain confidential information intended only for the person (s) named above. Any other distribution, copying or disclosure is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original to us without making a copy.

RECEIVED
CENTRAL FAX CENTER

012/020

MAY 03 2005

Attorney Docket No. VPI/00-117

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Jean-Damien Charrier et al.
Application No. : 09/877,832 Confirmation No. : 9982
Filed : June 7, 2001
For : CASPASE INHIBITORS AND USES THEREOF
Group Art Unit : 1624
Examiner : Venkataraman Balasubramanian

Cambridge, Massachusetts
May 3, 2005

Hon. Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AND REPLY TO OFFICE ACTION

Sir:

This is in reply to the November 3, 2004 Office Action in the above-identified application. Applicants have submitted herewith a three-month extension of time to respond to the Office Action. The time for reply to this Office Action is, therefore, up to and including May 3, 2005. Accordingly, this reply is timely filed.

The Amendments to the claims begin at page 2 of this Reply. Remarks begin at page 8 of this Reply.